[en] Objective: To study the CKMBmass by immunoturbidimetric method and verify the consistency of CKMBmass and method of chemiluminescence platform creatine kinase isoenzyme MB (CK-MB) by testing clinical random samples and samples of CKMB inverted in the active method in clinical setting. The receiver operating characteristic (ROC) curve was referenced to the clinical judgment with gold standard of high-sensitivity troponin I to verify the accuracy of CKMBmass. Methods: CKMBmass was detected by Beckman AU5811 biochemical analyzer, while CK-MB and high-sensitivity troponin I (cTnI) were detected by Abbott i2000 chemiluminescence meter. 24 inverted samples of CKMBmass and CK-MB were collected to verify the consistency of the measured values. 45 serum samples of CKMBmass and CK-MB were detected at random to verify their correlations. CKMBmass and cTnI were used to measure AMI group samples and non-AMI samples simultaneously. The results were analyzed using ROC curve to verify the accuracy of CKMBmass. Results: In 24 inverted samples, the CKMBmass measurement was the same as the Abbott CK-MB measurement, and the direction of negative-positive was the same. In 45 random samples, the regression equation of the CKMBmass and Abbott CK-MB measurement was Y = 1.002X-0.080. There was a significant difference in the non-AMI group (P < 0.05), and CKMBmass AUC was 0.963. Conclusion: The anti-interference ability and correlation of CMBMmass are consistent with the chemiluminescence method CK-MB. The diagnosis of AMI is highly consistent with the high-sensitivity cTnI, which meets the clinical needs. (authors)